CRPC w/ Bone Metastases VL

Bone Targeted Therapy with Zoledronate or Denosumab is Required in Men with mCRPC Responding to Anticancer Therapy - Noel Clarke

Details
Noel Clarke a Consultant Urologist at Salford Royal Hospital presents in opposition of treating all patients with bone-targeted therapy during his portion of the debate on bone-targeted therapy with zoledronate or denosumab. Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Bone Targeted Therapy with Zoledronate or Denosumab is Required in Men with mCRPC Responding to Anticancer Therapy - Cora Sternberg

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Use of Radium-223 in Clinical Practice: a Radiation Oncologist's Experience - Daniel Spratt

Details
Dr. Daniel Spratt begins his video lecture with an overview of Radium-223 and highlights from the ALSYMPCA trial and improvement of overall survival. Dr. Spratt discusses the current use of Radium-223 and how applicable ALSYMPCA’s results are for today’s patient. The lecture concludes with a look at how to optimize the use of the use of Radium-223. Importantly, by giving Radium-223 as 3 rd or 4 th...

Operationalization of Radium-223 Therapy for Bone Metastases - Eric Rohren

Details
An excerpt from Dr. Eric Rohren's state of the art presentation on Radium-223. This discussion includes the operationalization of Radium-223 at MD Anderson. In addition, a review of different agents available for imaging skeletal metastases with metastatic castration-resistant prostate cancer and a look at patient prognosis and survival data. Biography: Eric Rohren, MD. PhD., a national leader in...

Abiraterone Acetate and Radium-223 in Castrate-Resistant Prostate Cancer: Finding the Right Treatment at the Right Time - Charles Ryan

Details
Chuck Ryan's presentation on Abriaterone Acetate and Radium-223 and finding the right treatment at the right time for the right patient. This discussion is lead by reviewing a patient case study and the practical considerations in the use of novel hormonal agents in the post-ADT setting. Dr. Ryan provides take home points for proactive metastatic castration-restistant prostate thearpy and benefits...

Cristina Nanni on Flucicovine F18 (FACBC) in Prostate Cancer - State of the Art Presentation

Details
Cristina Nanni, MD. a leader in prostate cancer nuclear imaging, presents the data on Flucicovine F18 (FACBC), a new radiopharmaceutical and its application in diagnosisng biochemical replapse in post prostatectomy patients based upon a rising PSA. Dr. Nanni also presents details on its mechanism of action in prostate cancer cells, the current clinical approach and reviews of patient case studies...

eRADicAte: A Study of Radium-223 with Abiraterone Acetate in Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases - Neal Shore

Details
Neal Shore, MD. presents the eRADicAte study, an open label phase two clinical trial of radium-223 with concurrent administration of abiraterone acetate plus prednisone in castration-resistant prostate cancer (CRPC) subjects with symptomatic bone metastases without visceral metastases. These results were first presented at the AUA 2016. Potential synergy exists in combining radium-223 and abirater...

Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer - Phillip Koo

Details
In this 5 for 5 Hot Topics, Phillip Koo, MD. presents the clinical background of Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer, the first FDA-approved F18 PET Imaging Agent indicated in for use in patients with suspected recurrent prostate cancer. Dr. Koo discusses its use for men with suspected prostate cancer recurrence based on elevated PSA levels following...

Detection of Metastatic Disease in Prostate Cancer: Past, Present, Future- Phillip Koo

Details
Detection of Metastatic Disease in Prostate Cancer: Past, Present, Future. Philip Koo discusses the evolving use of imaging in the detection of bone metastasis in the prostate cancer patient. Phillip Koo, MD Associate Professor, Radiology - Nuclear Medicine University of Colorado School of Medicine Aurora, Colorado Dr. Koo is the associate professor of radiology, nuclear medicine at the University...